Render Target: SSR
Render Timestamp: 2024-11-14T22:38:16.220Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:56:26.444
Product last modified at: 2024-11-06T19:30:09.899Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

BCL11A (D4E3P) Rabbit mAb #75432

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 100-145
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Simple Western™ 1:50 - 1:250
    Immunoprecipitation 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    BCL11A (D4E3P) Rabbit mAb recognizes endogenous levels of total BCL11A protein.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val247 of human BCL11A protein.

    Background

    BCL11A is a zinc finger-containing transcriptional repressor that is important for normal hematopoiesis (1). Alternative splicing of the BCL11A transcript results in several isoforms of the protein (2). BCL11A is required for the early stages of B lineage commitment and mice lacking BCL11A fail to develop B cells (1). Mice deficient in BCL11A also fail to develop plasmacytoid dendritic cells (3). In addition, BCL11A regulates the switch from fetal to adult hemoglobin by repressing expression of fetal hemoglobin in adult erythroid cells (4). Since expression of fetal hemoglobin can decrease the severity of hemoglobin disorders in adults, BCL11A is a potential therapeutic target for these diseases (4). BCL11A was also recently identified as a component of the mammalian SWI/SNF complex (5). BCL11A is required for morphogenesis and terminal differentiation of dorsal spinal neurons (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.